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Abstract. Blood-brain barrier (BBB) disruption is one of the hallmarks of multiple sclerosis (MS). It is incompletely understood
whether BBB disruption is the initial MS event leading to MS lesion formation or whether it is merely a consequence of cellular
infiltration in the central nervous system (CNS). The presence of gadolinium enhancing (Gd+) lesions on serial brain MRI scans
is frequently used to evaluate BBB disruption. The presence of Gd enhancement has therefore been used as a reference for
most works evaluating promising biomarkers of BBB disruption that are reviewed here. These promising biomarkers include
cytokines and chemokines, and their receptors, cell surface markers, and matrix metalloproteinases and their natural inhibitors.
At this time, none of these markers have been shown as sensitive as the presence of Gd enhancement to reflect BBB disruption.
However, MRI scanning is not only unpractical and expensive; it may also under represent the overall extent of BBB disruption.
Developing new MS biomarkers that are sensitive and specific for BBB disruption could 1) improve the monitoring of disease
activity; 2) improve the monitoring of response to MS therapies which target BBB disruption; and 3) advance our understanding
of dynamic MS processes participating in BBB disruption.
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1. Introduction
Blood-brain barrier (BBB) disruption is one of the
hallmarks of multiple sclerosis (MS). It is incompletely
understood whether BBB disruption is the initial MS
event leading to MS lesion formation or whether it is
merely a consequence of cellular infiltration in the cen-
tral nervous system (CNS). In fact, disruption of vas-
cular barriers in the CNS of patients with MS occurs
not only at the level of the BBB, but also at the level
of the blood-spinal cord barrier [1]. The presence of
gadolinium enhancing (Gd+) lesions on serial brain
and spinal cord MRI scans seems to be the most robust
biomarker of BBB disruption at this time. Therefore,
Gd enhancement has been used as a reference for most
works evaluating promising biomarkers of BBB dis-
ruption. However, MRI scanning is not only unpracti-
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cal and expensive; it may also under represent the over-
all extent of BBB disruption. Novel MS biomarkers
which are sensitive and specific for CNS blood-barrier
disruption and less expensive and easier to obtain than
MRI scans with Gd injection, and which broadly re-
flect blood barrier disruption in the entire CNS could
help 1) to better monitor disease activity; 2) to monitor
response to MS therapies that target BBB disruption
such as interferon-β and natalizumab [2,3]; and 3) to
advance our understanding of dynamic MS processes
participating to BBB disruption.
2. The blood-brain and blood-spinal cord barriers
Because most of the work on CNS blood barriers
pertains to the BBB, this review will focus on biomark-
ers indicative of BBB disruption. The BBB is a com-
plex structure constituted by the assembly of several
cell types and matrix components [4,5]. The CNS mi-
croenvironment is important for neuronal function. The
BBB is involved in its maintenance by protecting the
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brain parenchyma from abrupt metabolic changes and
by maintaining apico-dorsal polarity. The selectively
permeable BBB is rapidly responsive to physiological
and pathological stimuli and plays a key role in main-
taining the distinctive CNS metabolic and immunoreg-
ulatory homeostasis [4,5]. The barrier is present in a
complex cellular system in which tight junctions be-
tween endothelial cells play a crucial role. Cells that
compose the BBB in association with the basal laminae
include endothelial cells, pericytes, perivascular mi-
croglia, and astrocyte processes. The unique properties
of CNS endothelial cells compared with those present
in other organs are induced by the neural environment
during the development of the vascular system. Astro-
cytes that tightly appose end feet onto the abluminal
side of brain capillaries seem to be important for the
induction and maintenance of the endothelial barrier.
2.1. The BBB in MS
The physiological low level of BBB exchange ne-
cessitates that cerebral endothelial cells (CEC) main-
tain multiple transporters for glucose and amino acids.
CEC also express cholinesterases, monoamine oxidase,
alkaline phosphatase and aromatic decarboxylases for
catabolizing humoral transmitter substances [6]. γ-
glutamyl transpeptidase appears to be another marker
specific for CEC. In addition to these surface enzymes,
CEC share common endothelial markers such as low
density lipoprotein (LDL) and insulin receptors [6].
In the BBB, the tight and adherens junctions are the
subcellular structures that maintain the restrictive prop-
erties of the BBB. BBB hyperpermeability has been
linked to pathology in microvascular tight junctions
(TJ). The evaluation of MS brains has shown that the
TJ-associated protein zonula occludens-1 (ZO-1) has
an abnormal pattern in oil-red O (ORO)-positive ac-
tive plaques, affecting 42% of vessel segments, but
this pattern is less frequent in ORO-negative inac-
tive plaques (23%), normal appearing white matter
(NAWM) (13%), and normal (3.7%) and neurological
controls (8%) [6]. A similar pattern was found irre-
spective of the vessel size, supporting a causal role for
diffusible inflammatory mediators.
2.2. Causes of BBB disruption
The BBB can be disrupted as a result of several pro-
cesses. Massive migration of white blood cells (WBC)
to the CNS or damage to blood vessel lining and sur-
roundings (e.g., release of toxic factors in ischemia,
or histamine in inflammation) can result in temporary
BBB loss of integrity. On the contrary, neo vessels
such as in cases of CNS tumor or vascular malforma-
tion may display an unusual fragility that can result in
permanent increase of BBB permeability.
2.3. Consequences of BBB disruption
A consistent MS feature is the transient or chronic
loss of BBB impermeability. BBB disruption results in
accumulation of serum proteins outside vessel walls [6–
8] and may in turn facilitate cell migration to CNS.
BBB disruption can be visualized in vivo by injection
of gadolinium (Gd), a contrast agent of small molecular
weight that diffuses easily outside a BBB that has lost
its integrity. Various degrees of disruption can be found
from minimal and delayed Gd enhancement reflect-
ing mild changes of permeability to massive and early
Gd enhancement reflecting significant disruption [8,9].
The BBB breakdown may precede clinical signs, and
constitute one of the first stages in the formation of most
T2-bright areas, at least in relapsing forms of MS [9].
Gd enhancement in new or enlarging MS lesions lasts
several weeks. Although the presence of Gd enhance-
ment parallels a significant BBB leakage, it does not
measure inflammation per se as once BBB permeability
is restored, CNS inflammation may persist for a while.
Neurologists have initially attempted to identify
biomarkers of MS activity by comparing various serum
marker levels in patients identified as stable (no re-
lapse) and those with recent relapses. Later, MRI scans
demonstrated that macroscopical changes occurred sig-
nificantly more often than clinical changes [9], thereby
impairing the ability to identify biomarkers of disease
activity when using purely clinical outcomes. In the
past decade, the use of Gd enhancing MRI scans has
enabled investigators to correlate more tightly several
biomarkers to infraclinical MS activity measured by
the presence of enhancement after Gd injection.
Several factors may limit our ability to use the pres-
ence of Gd enhancement as the ultimate marker of BBB
disruption. The presence of Gd enhancement varies ac-
cording to the dose of Gd that is administered, the time
elapsed between Gd injection and image acquisition,
and the severity of BBB disruption. This explains why
mild chronic BBB leakage may not be detectable when
MR images are obtained soon after the injection of Gd,
as in progressive models of MS the presence of Gd en-
hancement may be delayed [10]. Further, it is unclear
whether the best outcome measures of BBB disrup-
tion should be presence of Gd enhancement, number
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Table 1
Adhesion molecules and their ligands involved in diapedesis (modified from reference 15)
Adhesion Molecules Cellular Expression Ligands Main Function
Immunoglobulin Superfamily
ICAM-1 E, T, B, Ma, Mi, A LFA-1, MAC-1, CD43 T cell migration
VCAM-1 E, Ma, Pe VLA-4, α4β7 T cell and macrophage migration
PECAM-1 E, T (naive), Ma, NK PECAM-1, αvβ3 T cell, natural killer and macrophage migration
Integrins
VLA-4 (α4β1) T, B, Ma VCAM-1, FN, VLA-4, α4β7 T cell and macrophage migration
LPAM-1 (α4β7) Memory T cells VCAM-1, FN, MAsCAM-1 Memory T cell migration
LFA-1 (αLβ2) Ma, Mi ICAM-1, -2, -3 T cell and macrophage migration
Mac-1 (αMβ2) Ma, Mi, NK ICAM-1, FN, C3bi Macrophage migration
Selectins
E-selectin E sLx, ESL-1 T cell rolling
L-selectin T, B, Ma sLx, mucines Rolling of T cell and macrophage
P-selectin E sLx, PSGL-1 Macrophage rolling
Other
CD44 T, B, Ma, A, O MEC T cell migration
Acronyms: C3bi: complement 3bi; ESL-1: L-selectin ligand; FN: fibronectine; ICAM-1: intercellular adhesion molecule-1; LFA-1: leuko-
cyte function-associated molecule-1; LPAM-1: lymphocyte Peyer’s patch adhesion molecule-1; Mac-1: macrophage glycoprotein associated
with complement receptor function; MAdCAM-1: mucosal adressin cell-adhesion molecule-1; PECAM-1: platelet/endothelial cell-adhesion
molecule-1; PSGL-1: P-selectin glycoprotein ligand-1; sLx: sialyl-Lewisx; VCAM-1: vascular-cell adhesion molecule-1; VLA-4: very late
antigen-4.
A: astrocytes; B: B lymphocytes; E: endothelial cells; Ma: macrophages; Mi: microglia; NK: natural killer cells; O: oligodendrocytes; Pe:
pericytes; T: T lymphocytes.
of enhancing lesions, volume of Gd enhancement or
quantification of Gd enhancement signal over the entire
brain. Second, most studies correlating biomarkers of
interest to the presence of Gd enhancement rely purely
on brain MRI scans. Therefore, the presence of spinal
Gd enhancement in these instances is not part of the
equation.
3. Markers associated with BBB disruption
Several markers have been studied for their ability to
reflect BBB disruption in MS. Most of these are indi-
rect markers of underlying biological processes partic-
ipating in BBB disruption, e.g., markers of cell activa-
tion associated with BBB disruption except maybe for
zonulin and endothelial microparticles [11,12].
3.1. Markers specific of BBB disruption
An ideal marker of BBB disruption should be either
specific for brain endothelium and therefore not found
on other endothelial cell types, or be brain derived.
Several markers may be specific for the BBB such as γ-
glutamyl transpeptidase, cholinesterases, monoamine
oxidase, alkaline phosphatase, aromatic decarboxy-
lases, tight junction proteins (occludin, claudins, ZO-1
to -3, cingulin, junctional adhesion molecules) and ad-
herens junction proteins (VE-cadherin, catenins) [13].
There are no published reports on the levels of these
markers in correlation with BBB disruption in MS.
Regarding markers of brain damage and BBB disrup-
tion, only a few studies report increased levels of brain
derived proteins such as S100β after brain trauma or
stroke [reviewed in 14]. S100β is a protein primarily
synthesized in the brain by astrocyte end feet processes
and is quickly released from the brain into the blood
when the BBB is disrupted [14]. While S100β appear-
ance in plasma correlates well with an opening of the
BBB, it has also been shown to increase in plasma or
CSF as a consequence of other disease processes not
limited to the CNS. At this time, there is no evidence of
such S100β increase related to BBB disruption in MS.
An ideal marker of BBB disruption should be mea-
surable in serum or blood as opposed to CSF for ease of
sampling and be virtually undetectable in healthy sub-
jects. It should show distinct alterations in response to
insults that are correlated with the severity of damage,
represent disruption of BBB or blood spinal cord bar-
rier, and be reproducible and inexpensive. Depending
on the biomarker studied, a possible lag time between
the increase of the biomarker level and the occurrence
of BBB disruption must be considered [42]. In fact,
some markers may relate to processes preceding BBB
disruption while others may relate to processes occur-
ring after BBB disruption has occurred [29].
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Table 2
Adhesion molecules in MS and their relation to BBB disruption
Serum CSF Patients References
CD54
sICAM-1 (E, T, B, Ma, Mi, A) ↑ ↑ Active disease (CS)
Active clinical or MRI RRMS (LG)
16, 17, 18
↑ − levels in RR > SP > PP (LG)
− high sICAM in patients with higher # Gd+
− Gd− patients had lower sICAM-1
22
sICAM-1 index ↑ − active RRMS (CS)
− index correlated with Gd+ volume
21, 23
CD106
sVCAM-1 (E, Ma, Per) ↑ − levels in RR > SP MS (CS)
− levels higher in Gd+ > Gd−
19
sVCAM-1 index ↑ Levels correlated with Gd+ volume (CS) 23
CD62
sL-selectin (T, B, Ma) ↑ − levels in RR > SP MS (CS)
− levels higher in Gd+ > Gd−
19
↑ ↑ − levels higher in patients with Gd+
− levels correlated with size of Gd+
20
sE-selectin (E) → − MS patients (CS)
− Active clinical or MRI RR (LG)
18, 19
Endothelial Microparticles
Insoluble PECAM-1 (CD31+) ↑ − higher in RRMS than controls (CS)
(P, E, Mo, N) − higher in patients with exacerbation than remission
− higher in patients with Gd+ than Gd−
11, 24
CD51 ↑ − higher in RRMS than controls
(integrin αVβ3) − same levels in patients with exacerbation and remission
(E, B, Mo) − same levels in patients with Gd+ and Gd− 11
Abbreviations: LG: longitudinal, CS: cross-sectional, RR: relasping remitting, SP: secondary progressive. A: astrocytes; B: B
lymphocytes; E: endothelial cells; Ma: macrophages; Mi: microglia; NK: natural killer cells; O: oligodendrocytes; Pe: pericytes;
T: T lymphocytes.
3.2. Non specific markers associated with BBB
disruption
Multiple studies have evaluated the potential corre-
lation of non specific markers involved in BBB disrup-
tion and are reviewed below. These include markers
of cell adhesion, activation and attraction such as ad-
hesion molecules, cytokines, chemokines and their re-
ceptors; and markers of diapedesis such as endothelial
tight junctions, and matrix metalloproteases (MMPs)
and their natural tissue inhibitors (TIMPs).
3.2.1. Markers of cell adhesion, activation and
attraction
3.2.1.1. Adhesion molecules as markers of BBB
disruption
The activation of several cell types is a prerequisite
for monocyte migration to the CNS. A tight regulation
of various cell adhesion molecules (CAMs) is necessary
for cell migration through tissues [see Table 1 adapted
from 15]. Monocyte migration involves sequentially
tethering, rolling via up-regulation of L-selectins (on
leukocytes) and P-selectins (on endothelial cells), and
monocyte arrest via up-regulation of E-selectins (on
endothelial cells) and integrins (on leukocytes).
Several CAMs have been measured in the serum and
CSF of patients with MS as potential markers of BBB
disruption (Table 2) [11,16–24]. The main ones include
soluble CD54 (ICAM-1), CD106 (VCAM-1), CD62
(L, P and E selectins), and endothelial microparticles
(CD31 and CD51). Table 2 recapitulates published
data for various markers in serum and CSF, the cells
expressing or synthesizing these markers, and study
design and patients characteristics.
Most CAMs are expressed by several cell types (see
Tables 1 and 2), which decreases their potential speci-
ficity as markers of BBB disruption. The expression
of CAMs at the cell surface is up-regulated in part by
proinflammatory cytokines. CAMs are also shed in
serum as soluble products. In vivo, soluble CAMs are
detectable in serum and CSF and are believed to reflect
cell surface expression levels. The factors underlying
increased soluble CAM levels are unclear as increase
in both production or membrane cleavage could result
in these elevated CAM serum levels. The role of solu-
ble CAMs remains unclear although it is suspected that
they could inhibit cell adhesion.
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Table 3
Cytokines and their receptors as markers of BBB disruption
Blood Patients References
TNF and TNF receptor (TNF-R)
TNFα → RR/SP, no relation with MRI activity 26
TNFα mRNA ↑ Active clinical or MRI RR patients (LG) 18
sTNF-Rp60 ↑
sTNF-Rp60 ↑ Higher in patients with Gd+ than Gd− 19
Higher in RR than chronic progressive (CS)
LN-α → No correlation with Gd+ 27
IL-2 and IFN-γ
IL-2 secreting cells ↑ − higher in RRMS, correlated with total # Gd+ 27
IFN-γ secreting cells ↑ − Trend only (LG)
IFN-γ mRNA → Unchanged with MRI activity
IL-12
IL-12p40 mRNA ↑ Higher in RR/SP patients 28
IL-12p35 mRNA ↓ Decreased when new MRI lesions appear
IL-10
IL-10 mRNA ↑ Higher in RR when new lesions appear
IL-10 ↑ Higher when Gd+ resolves 29
LG: longitudinal, CS: cross-sectional, RR: relasping remitting, SP: secondary progressive.
Gd−: no gadolinium enhancing lesions.
Gd+: presence of gadolinium enhancing lesions.
Although several CAMs have been reported to be
associated with BBB disruption [11,16–24], none are
in fact specific or highly predictive of BBB disruption.
While increased levels have been reported in patients
with MS, there is a significant overlap with normal val-
ues or values in non-active MS patients. In fact, there is
no data on sensitivity and specificity of these markers
as they relate to BBB disruption. Interestingly, soluble
E-selectin which is specific for endothelial cells is not
elevated in patients with MS or increased during levels
of disease activity [18,19]. Endothelial microparticles
(EMPs) unlike other CAMs may reflect more directly
the status of BBB endothelium in MS as cerebral en-
dothelial cells activated by cytokines and chemokines
shed EMPs into plasma [11]. These small membrane
vesicles bear adhesion molecules from the activated
parent endothelial cell. EMPs have been studied as
markers of endothelial stress. Some of the markers
carried by EMPs include PECAM-1 (CD31), CD51,
endoglin (CD105), E-selectin, and VCAM-1. High
plasma levels of EMP carrying CD31 are associated
with the presence of contrast enhancing lesions on brain
MRI scans in MS patients and may represent a new
marker of disease activity [11]. Although the overlap
between values of EMPs carrying CD31 in active MS
patients and healthy individuals is much less than what
is seen with other CAMs, the use of this marker is lim-
ited by the fact that EMPs can be increased in serum as
the result of other inflammatory processes such as seen
in patients with systemic lupus erythematosus.
3.2.1.2. Cytokines and their receptors as markers of
BBB disruption
Cytokines are small proteins that participate as extra
cellular messengers in a wide range of host responses.
MS has been associated with several immunoregula-
tory defects. The activity of Th2 cells which secrete
the anti-inflammatory cytokines IL-4 and IL-10 ap-
pears reduced at the expense of an increased activity
for Th1 cells which secrete increased amounts of the
pro-inflammatory cytokines interferon-γ, TNF-α and
IL-2 [for review see 25]. IL-12 appears to be another
key pro-inflammatory cytokine in MS that is crucial for
Th1 differentiation.
Similarly to CAMs, cytokines and their receptors
are known to be involved in MS processes and have
been evaluated as potential markers of BBB disruption
(see Table 3) [18,19,26–29]. Several pro inflammatory
cytokines appear to be correlated with BBB disruption.
As reflected in published data, cytokines and their
receptors appear to be interesting markers for MS ac-
tivity but none are highly specific or predictive of BBB
disruption. Further, their levels fluctuate significantly
within and between patients. Their levels in patients
with MS also overlap with healthy controls as well as
across disease types and courses. This is likely ex-
plained by the fact that changes in cytokine serum lev-
els reflect a complex and intricate regulatory system
for immune processes rather than mere BBB disruption
alone. As a result, no specific cytokine or receptor level
is used in clinical research or in clinical practice which
would correlate with BBB disruption.
240 E. Waubant / Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis
3.2.1.3. Chemokines and their receptors as markers of
BBB disruption
Chemokines are released by several cell types
throughout the body and define patterns of leukocyte
migration to various organs guided by a restricted ex-
pression of their cognate receptors. For example,
CCR5 participates in the directed migration of T cells
into the CNS [30]. Chemokines have various effects
beyond leukocyte recruitment such as the modulation
of cytokine release and of nitric oxide production. The
release of chemokines and the expression of their re-
ceptors are significantly modified by inflammatory con-
ditions. Some chemokines contribute to inflammation
such as monocyte chemoattractant protein 1 (MCP-1)
whereas others such as fractalkine can limit inflamma-
tion.
Chemokines and their receptors are expressed dif-
ferentially on various cell types and under various
conditions. The regulation of a restricted number of
chemokines and their receptors appears to regulate the
traffic of inflammatory cells to the CNS and thereby
could correlate with BBB disruption. Although in-
creased numbers of CCR5-positive, IFNγ- and TNFα-
secreting lymphocytes have been reported during acute
MS exacerbations compared to controls, no MRI data is
available for these patients to confirm a correlation with
BBB disruption [31]. Recently, it was suggested that
CXCR3 expression on CD8-positive T cells correlated
with total T2 lesion volume, but no correlation was re-
ported for Gd enhancing lesions with CXCR3, CCR2
and CCR5 expression on CD4- and CD8-positive T
cells [32].
3.2.2. Markers of diapedesis
Markers of diapedesis include markers of BBB open-
ing and of damaged cerebral endothelial cells, and
markers that reflect the digestive ability of white blood
cells to migrate to CNS tissues.
3.2.2.1. Markers of BBB opening and damaged
cerebral endothelial cells
The main marker of an opening of endothelial tight
junctions, e.g., the major keeper of vascular barrier per-
meability, is zonulin. Although not specific for the
BBB, zonulin is a protein modulating tight junctions,
therefore playing a potentially crucial role in the mod-
ulation of BBB permeability in MS. One publication
reports 1.5- to 3-times elevated serum levels in patients
with relapsing remitting and secondary progressive MS
compared to controls [12]. In this work, the highest
levels of serum zonulin were reported in relapsing re-
mitting patients who had Gd enhancing lesions. Fur-
ther studies are needed to confirm the utility of this
protein as a biomarker of BBB disruption in MS.
3.2.2.2. Matrix metalloproteinases (MMPs) and their
natural inhibitors (TIMPs)
The balance between MMPs and their natural in-
hibitors (TIMPs) tightly regulates the digestion of the
extracellular matrix and basement membranes, and
thereby the migration of white blood cells to the CNS
and other organs. MMPs are classified according to
their substrates and structures and are reversibly inac-
tivated when bound to a TIMP. MMPs and TIMPs par-
ticipate in numerous physiological processes such as
scaring, blastocyst implantation, and angiogenesis as
well as pathological processes such as in rheumatoid
arthritis, tumor infiltration, and metastatic dissemina-
tion [33].
MMP substrates include extracellular proteins such
as collagen type I-VIII, gelatin, elastin, laminin but also
myelin basic protein and several growth factors. MMP-
2 and -9 may be interesting markers of BBB disruption
as they are the main MMPs for the degradation of colla-
gen type IV and gelatin which are the main constituents
of basal lamina. MMP-2 and -9 among others have been
studied in several models for experimental allergic en-
cephalomyelitis (EAE) [34–36]. Intravenous injection
of MMP-9 was shown to open the BBB in animals [37]
and MMP-9 levels are increased in EAE [34–36]. Hu-
man lymphocytes have been shown to produce several
MMPs (MMP-2, -7, -9, -15, and -24 among others)
and TIMPs [38–40] that are instrumental in T and B
cell migration in vitro as they regulate digestion of the
basal laminae [37,38]. These findings have prompted
the study of MMP-9 and TIMP-1 in MS and their re-
lation to BBB disruption as measured by the presence
of Gd enhancing lesions on brain MRI scans [41–43].
Several remarkable findings are summarized below.
First, levels of MMP-9 were reported to be elevated
in the serum of patients with relapsing remitting and
secondary progressive MS compared to controls [41–
46]. Further, the main MMP-9 inhibitor, TIMP-1 does
not seem to be increased in relation to MMP-9 suggest-
ing an imbalance towards an increased digestive activ-
ity (Fig. 1) [41–43]. The use of the MMP-9/TIMP-1
ratio seems to provide a better measurement of prote-
olytic activity. However, as seen in Fig. 1, serum levels
overlap significantly between MS patients and controls,
even - although to a lesser extent - when using the ratio.
Second, MMP-9 serum levels were reported to be
elevated in patients with Gd enhancing lesions as op-
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Fig. 1. Median serum levels for MMP-9 and TIMP-1, and MMP-9/TIMP-1 ratio in patients with relapsing remitting MS and controls [42].
Table 4
MMP-9/TIMP-1 predicts new gadolinium enhancement on subse-
quent brain MRI scan in RRMS [42]
P* Odds ratio * (95% CI)
High MMP-9 and TIMP-1 0.019 6.5 (1.4, 30.8)
Low MMP-9 and TIMP-1 0.043 4.7 (1.0, 21.3)
High MMP-9 and low TIMP-1 0.0006 21.5 (3.8, 121.4)
*versus reference category low MMP-9 and high TIMP-1.
Multivariate repeated measures logistic regression, levels di-
chotomized around median.
posed to those with no Gd lesions [43]. Further, higher
levels of MMP-9 or lower levels of TIMP-1 seemed to
predict the presence of Gd enhancing lesions the month
of or the month after samples were obtained from pa-
tients (Fig. 2 and Table 4) [42,43]. This relation was
found for MMP-9 and TIMP-1 as separate measures
but appeared to be stronger when those measures were
combined (Table 4) [42,43]. The predictive value of
MMP-9 and TIMP-1 may be stronger in relapsing re-
mitting versus secondary progressive MS [42,43]. No
such relationship was reported for MMP-2 and TIMP-
2 [43].
Finally, interferon-β therapy which reduces BBB
disruption in MS appeared to result in lower levels of
serum MMP-9, and even more significantly in higher
levels of TIMP-1 in patients with relapsing remit-
ting and secondary progressive MS, re-adjusting their
MMP-9/TIMP-1 ratios towards normal values [43,47,
48].
While MMP-9 and TIMP-1 appear to be highly pre-
dictive of BBB disruption in relapsing remitting MS,
Fig. 2. Proportion of brain MRI scans with new gadolinium enhance-
ment the month after MMP-9 and TIMP-1 measures [42]. Category
groups include low MMP-9 and high TIMP-1 levels, high MMP-9
and high TIMP-1 levels, low MMP-9 and low TIMP-1 levels, and
high MMP-9 and low TIMP-1 levels.
they do not seem very specific of BBB disruption per
se as they may mostly reflect cell activation in general.
The cells contributing to MMP-9 and TIMP-1 elevation
include T and B cells, macrophages, and endothelial
cells. Because MMP-9 and TIMP-1 levels fluctuate
within and between patients, and are affected by infec-
tions, their use for a monitoring of the disease course
in MS is difficult at best. It is interesting to note that
the lack of a decrease of the MMP-9/TIMP-1 ratio dur-
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ing interferon-β treatment may predict the occurrence
of Gd enhancing lesions [43]. This suggests that the
MMP-9/TIMP-1 ratio should be further evaluated as a
surrogate of response to interferon-β.
4. Conclusions
To date, it has not been possible to identify biomark-
ers which would surpass Gd enhancement on brain MRI
scans as measures of BBB disruption in vivo. Some
would argue that alternative markers of BBB disrup-
tion might not be needed. Could such markers replace
enhanced MRI scans or would they simply help us bet-
ter understand disease processes? The need for an im-
provement of our ability to monitor the therapeutic re-
sponse to agents that target BBB disruption appears to
be the most critical.
Promising biomarkers of BBB disruption should be
evaluated in conjunction with Gd activity on MRI scans
obtained longitudinally as opposed to cross-sectional
MRI studies or purely clinical outcomes, as this seems
to be a more sensitive outcome. However, it remains
unclear whether brain and spinal cord MRI scans should
be combined to truly reflect BBB and blood-spinal cord
barrier disruption.
It is unfortunate that published studies of MS
biomarkers of BBB disruption have used various
methodological approaches that have prevented a com-
parison of findings across studies. This argues for
changing our practice. As new tools such as proteomics
become available, we should evaluate promising mark-
ers of BBB disruption concomitantly in order to com-
pare their sensitivity and specificity to predict BBB dis-
ruption. When appropriate, markers should be eval-
uated in parallel with their “inhibitor” or counterpart
in order to assess a more global balance, such as IL-
10 and IL-12, or MMP-9 and TIMP-1. As no single
marker appears to be as good as Gd enhancing MRI
scans to monitor BBB disruption, we should likely fo-
cus on a combination of markers to improve sensitiv-
ity and specificity to detect BBB disruption. Improved
understanding of BBB disruption is needed in MS. To
advance our knowledge, measures of various biomark-
ers should be taken during clinical trials and natural
history studies, or at least sample collection should be
organized to allow for future such studies.
Finally, a specific effort should also be undertaken
together with biostatisticians to advance the methodol-
ogy of how best to evaluate promising biomarkers of
BBB disruption. It appears that cross sectional studies
of biomarkers of BBB disruption may be sub-optimal
or even too crude in this day and age to take into ac-
count the complexity of MS processes, whereas lon-
gitudinal studies take into account fluctuations of sev-
eral biological changes (e.g. serum and MRI) concomi-
tantly [28,29,42,43]. This approach allows the use of
biostatistical tools that also account for within-patient
fluctuations [29,42,43]. The use of such models may
permit concomitant analysis of several related or unre-
lated markers and may result in higher power to identify
relevant markers of BBB disruption.
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